Dr Reddy’s launches cancer drug generic in US

Our Bureau Hyderabad | Updated on June 19, 2020 Published on June 19, 2020

Pharma major Dr Reddy’s Laboratories Ltd has launched abiraterone acetate tablets, a therapeutic equivalent generic version of Zytiga, in the US market.

The drug has been approved by the US Food and Drug Administration (USFDA).

Zytiga is a trademark of Johnson & Johnson Corporation. The Zytiga brand and generic market had US sales of approximately $454 million for the 12 months ended March 2020, according to IQVIA Health.

Hyderabad-based Dr Reddy’s abiraterone acetate is available in 250 mg tablets in bottle count sizes of 120, according to a release.

Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with rednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Published on June 19, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.